SCHEMBL25764635

SCHEMBL25764635

CCNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)CCCCCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 4/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FOLH1 Q04609 1/20 0.40
FAAH O00519 2/20 0.40
OPRD1 P41143 1/20 0.40
ACE P12821 3/20 0.40
ACE2 Q9BYF1 3/20 0.40
PSMB5 P28074 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25881766 1.00 OPRL1 (0.42) OPRL1ALDH1A1SMN1; SMN2FOLH1FAAH
SCHEMBL27268254 0.94 OPRL1 (0.43) OPRL1ALDH1A1SMN1; SMN2FOLH1OPRD1
SCHEMBL25748810 0.93 OPRL1 (0.41) OPRL1ALDH1A1SMN1; SMN2FOLH1OPRD1
SCHEMBL23515709 0.90 FOLH1 (0.43) OPRL1ALDH1A1SMN1; SMN2FOLH1FAAH
SCHEMBL25649781 0.89 OPRL1 (0.41) OPRL1ALDH1A1SMN1; SMN2FOLH1OPRD1
SCHEMBL23680214 0.87 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2FOLH1HDAC3HDAC4
SCHEMBL24760256 0.87 OPRL1 (0.39) OPRL1ALDH1A1SMN1; SMN2OPRD1PSMB5
SCHEMBL22757206 0.87 OPRL1 (0.39) OPRL1ALDH1A1SMN1; SMN2OPRD1ACE
SCHEMBL24342162 0.86 OPRL1 (0.39) OPRL1ALDH1A1SMN1; SMN2OPRD1ACE
SCHEMBL26595672 0.86 OPRL1 (0.41) OPRL1ALDH1A1SMN1; SMN2OPRD1ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685742-B2 Anti-tumor compound and preparation method and use thereof RCC2, REN, VHL OPRL1 3888/4885ALDH1A1 3602/4885SMN1; SMN2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.